Market Place
Sourcing Support
Ipsen doubles up in TCEs for cancer, adding Biomunex drug
04 Dec 2024 //
PHARMAPHORUM
Biomunex Signs Exclusive Licensing Agreement With Institut Curie
04 Mar 2024 //
BUSINESSWIRE
Biomunex Announces the Start of Phase 1 for First-in-class Bispecific Antibody
24 Jan 2024 //
BUSINESSWIRE
Biomunex Presents Results on Disruptive MAIT Cell Redirection Approach
12 Apr 2023 //
BUSINESSWIRE
Biomunex Appoints Dr. Simon Plyte as Chief Scientific Officer
25 Apr 2022 //
CONTRACTPHARMA
Biomunex and Institut Curie in new strategic collaboration for cancer treatment
07 Feb 2022 //
HEALTHCAREAFRICA
Onward and Biomunex Enter into a Worldwide Exclusive License
16 Feb 2021 //
PRNEWSWIRE
Biomunex, Onward Ink Strategic Antibody Development Pact
16 Feb 2021 //
CONTRACTPHARMA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.